Cellipont Bioservices and WuGen Join Forces for CAR-T Therapies

• Cellipont Bioservices and WuGen have signed an agreement for the clinical manufacture of WuGen’s off-the-shelf CAR-T cellular therapies.

• Cellipont Bioservices will provide the technology transfer and production of Wugen’s allogeneic CAR-T cell therapies.

• Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.

Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), and WuGen, Inc., a clinical-stage biotechnology company, have announced the signing of an agreement for the manufacturing of their CAR-T cell therapies. The agreement was signed on March 14, 2024, marking a significant milestone in the field of cell therapy.

Under the agreement, Cellipont Bioservices will be providing the technology transfer and production of Wugen’s allogeneic CAR-T cell therapies at their new purpose-built 76,000 sq. ft. manufacturing facility. This collaboration is set to advance the development and manufacturing of CAR-T therapies, leveraging Cellipont Bioservices’ expertise in cell therapy manufacturing.

Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Their investigational cell therapies originate from healthy donors and are further engineered to enhance their function of eliminating cancer cells. These therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML), and T-cell malignancies.

“We are excited to collaborate with Cellipont Bioservices, leveraging their expertise in cell therapy manufacturing to carry out our mission of bringing innovative CAR-T cell therapies to patients in need. This new partnership helps enable Wugen to achieve our mission to help patients with hematological malignancies with off-the-shelf cell therapies,” said Kumar Srinivasan, Ph.D., MBA, president and CEO of Wugen.

“We are thrilled to partner with Wugen, Inc. in advancing their groundbreaking CAR-T cell therapies. This collaboration underscores our commitment to driving innovation and accelerating the development of life-saving treatments for patients worldwide,” said Edwin Beale, CCO of Cellipont.